Interestingly, FAK inhibition prevents tumor rebound after the cessation of antiangiogenic therapy through the inhibition of tumor angiogenesis, platelet-induced tumor cell proliferation, and vascular leakage (Figure 4A) [200,201,202,203]. This evidence concerns the gene PTK2 and neoplasm.